Chonluten is a Khavinson peptide bioregulator — the synthetic tripeptide Glu-Asp-Gly ("EDG"), targeted at bronchopulmonary/respiratory tissue (also called Bronchogen).
Class
Khavinson peptide bioregulator; synthetic tripeptide Glu-Asp-Gly (EDG), respiratory-targeted. Single compound.
Mechanism
Chonluten is a Khavinson short peptide bioregulator proposed to act through direct interaction with promoter-region DNA to modulate tissue-specific gene expression at low concentrations. In respiratory tissue it is described as regulating stress-response genes (c-Fos, HSP70), antioxidant enzymes (SOD), and inflammatory mediators (COX-2, TNF-alpha), restoring normal expression patterns in bronchial epithelium.
Research summary
The few indexed documents are on-topic Khavinson-family papers (ultrashort-peptide regulation; peptides considered in the COVID-19 context). Chonluten has been studied for bronchial and pulmonary cell biology and age-associated respiratory-tract function.
Epistemic caveat: the literature comes essentially from Khavinson's St. Petersburg Institute of Bioregulation and Gerontology and Russian academic journals (for example, the Bulletin of Experimental Biology and Medicine) — a single group, working in preclinical and gerontology models, with no controlled human trials and little independent replication.
Human clinical trial data
No human clinical trial has established administration parameters for Chonluten; VialTalk does not provide community-sourced dosing.
Clinical / safety context
Not approved in any major jurisdiction; sold research-use-only. Reported as well tolerated in the originating literature; no independent safety dataset.
Evidence quality — Limited / single-group
The compound is mechanistically interesting but evidentiarily weak from an independent standpoint: single-group, preclinical, with no controlled human trials.
Notes
Chonluten = EDG tripeptide (Glu-Asp-Gly), a lung/bronchial Khavinson bioregulator (also called Bronchogen). Same family as Thymogen, Ovagen, Prostamax, and Epitalon.